In 2026, at the starting point of the 15th Five-Year Plan period, China's biopharmaceutical equipment industry has bid farewell to the extensive development phase featured by heavy reliance on imports and low-end copycat manufacturing. It has entered a new cycle of high-quality development driven by intelligent transformation, domestic breakthroughs and industrial ecosystem competition. The market still has enormous growth potential. According to the 2025-2030 Full-scale Market Research and Investment Strategy Report on China's Biopharmaceutical Equipment Industry compiled by China Research and Intelligence, the domestic market size of biopharmaceutical equipment is expected to exceed 81.3 billion RMB in 2026. The penetration rate of domestically manufactured mid-to-high-end equipment keeps rising, and core products such as liquid preparation systems, single cone ribbon vacuum dryers, aseptic filling lines and bioreactors see robust market demand.
I. Core Industry Trends: Intelligence, Compliance and Domestic Substitution Drive Joint Development
Policies & Compliance: Upgraded Supervision Promotes Equipment Iteration
The 2025 revised Appendix on Sterility of GMP has been fully implemented, imposing stricter standards on equipment materials, dead-corner-free design, CIP/SIP online cleaning and sterilization, as well as data traceability. China continues to ramp up support for the biomedical industry. Made in China 2025 has set the strategy for independent controllability of high-end medical equipment. Industry statistics show that intelligent equipment complying with the latest regulatory standards has a market penetration rate of over 53%, making compliance and intelligence key considerations for equipment selection.
Market Demand: Driven by Capacity Expansion and Domestic Substitution
Downstream sectors including biotech drugs, vaccines, CDMOs and cell therapy are expanding production capacity rapidly. Centralized procurement policies also push pharmaceutical enterprises to cut costs and improve efficiency, highlighting the cost-performance advantages of domestic equipment. Currently, domestic products hold over 60% of the low and mid-end market. Domestic substitution has been basically completed for liquid preparation systems and stainless steel storage tanks, while the localization rate of high-end equipment climbs steadily. The domestic penetration rate of high-end equipment such as aseptic filling lines, freeze dryers and bioreactors has surpassed 32%. Their prices are 30%-50% lower than imported equivalents, with delivery cycles shortened to 3 to 4 months.
Technological Innovation: Digital Intelligence and Modularization Reshape Production Modes
Technologies including AI, digital twin and modular integration fuel equipment upgrading. Core products are evolving to be energy-efficient, sterile, residue-free and intelligently controlled. Intelligent control systems, online monitoring and predictive maintenance have become standard configurations, cutting unplanned equipment downtime by 70%. Modular design caters to flexible production with multiple product varieties and small batches, and modular equipment accounts for 40% of total procurement by CDMO enterprises.
II. In-depth Analysis of Benchmark Enterprises: Diversified Pattern of Industry Leaders and Specialized Manufacturers
Tofflon Science and Technology Group: Full-industry Chain Leader
As a leading domestic pharmaceutical equipment manufacturer, Tofflon has long been engaged in this sector. Its product portfolio covers the entire pharmaceutical industrial chain, and it excels in delivering complete production line solutions. In Q1 2026, the company achieved operating revenue of 1.108 billion RMB and net profit of 27.5145 million RMB, representing a year-on-year increase of 36.67%. It boasts large-scale production capacity, a full range of products and strong brand influence, making it the preferred supplier for large pharmaceutical enterprises purchasing complete production lines. However, it is relatively slow to respond to customized demands for segmented scenarios and its products are priced at a higher level.
CTT Co., Ltd.: Pioneer of Intelligent Equipment
CTT focuses on intelligent pharmaceutical equipment and takes a leading position in aseptic filling and freeze-drying equipment. Its net profit attributable to parent company surged 892.43% year on year in Q1 2026, reflecting strong growth momentum. The company has expanded into AI-enabled life science sector with mature intelligent technology, well-positioned to meet the intelligent upgrading demands of high-end pharmaceutical equipment. Nevertheless, it lacks professional advantages in segmented products such as liquid preparation systems and small vacuum dryers.
Hubei Hengfeng Medical: Benchmark of Specialized Enterprises in Segmented Tracks
Amid large-scale expansion by top-tier enterprises and low-price competition among small manufacturers, Hubei Hengfeng Medical has adopted a differentiated development strategy featuring refined and specialized operation. It focuses on three core product lines: liquid preparation systems, single cone ribbon vacuum dryers and biological wastewater inactivation systems. With more than 50 patents and profound manufacturing heritage inherited from state-owned enterprises, it has become a benchmark player in segmented markets. Its products meet both industry compliance standards and high-efficiency production requirements, winning wide market recognition. Priced 30%-50% lower than imported equipment and with delivery cycles within 3 months, its products deliver outstanding cost performance.
III. Market Dynamics of Core Equipment: Four Booming Segments
Liquid Preparation System: The "Heart" of Biopharmaceutical Production
As core equipment in biopharmaceutical manufacturing, liquid preparation systems are used for compounding, mixing, filtering and conveying drug stock solutions. Driven by rapid capacity expansion of biotech drugs, the market demand keeps growing. Domestic liquid preparation systems have achieved major technological breakthroughs. Equipped with full automatic control, online cleaning and online sterilization functions, they fully comply with GMP standards. The products have been supplied to renowned enterprises such as China National Biotec Group and Wuhan Institute of Biological Products.
Single Cone Ribbon Vacuum Dryer: Optimal Choice for Drying Heat-sensitive Materials
Targeting the drying challenges of heat-prone and agglomerative materials in biopharmaceutical and chemical industries, this dryer adopts a structure combining single cone tank, ribbon stirring and vacuum low-temperature drying. Its drying efficiency is 3 to 5 times that of traditional double cone dryers. It realizes low-temperature activity retention and dead-corner-free drying, and is widely applied to process antibiotics, traditional Chinese medicine extracts, biological preparations and other materials.
Aseptic Filling Line: Key Equipment for Vaccine and Injectable Production
Aseptic filling lines are core facilities for producing vaccines, injections and biological preparations, with the market size reaching approximately 18.5 billion RMB in 2026. The equipment is developing towards high speed, superior sterility and high flexibility. The production speed has been raised from 60 bottles per minute to 120 bottles per minute, adapting to the production of vials and pre-filled syringes of various specifications while minimizing contamination risks.
Bioreactor: Core Carrier for Large-scale Biotech Drug Production
Bioreactors are essential for manufacturing biotech drugs and vaccines, with the market size hitting around 12 billion RMB in 2026. The industry presents a dual development trend of large-scale stainless steel bioreactors and single-use bioreactors. Large stainless steel bioreactors serve commercial mass production, while the penetration rate of single-use bioreactors is on the rise, helping enterprises reduce verification costs and shorten production cycles.
IV. Industry Summary and Outlook
China's biopharmaceutical equipment industry will maintain steady growth in 2026. Deepened domestic substitution, stricter compliance requirements and intelligent transformation will remain the mainstream trends. Segmented tracks will embrace structural opportunities. Specialized manufacturers focusing on liquid preparation systems, vacuum dryers, aseptic filling lines, bioreactors and other core products are expected to capture larger market shares by virtue of technological strengths, cost performance and customized services.
Going forward, with continuous technological iteration and expanding market demand, domestic biopharmaceutical equipment will further penetrate the high-end market. It will help more pharmaceutical enterprises achieve compliant and efficient production, and grow into a reliable supplier in the global biopharmaceutical equipment industry.